

ATE OF MAILING

Thereby certify that this correspondence is, on the date below, being deposited with the U.S. Postal Service as first-class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Mark D. Lenhart

Appn. Title:

SUBSTANCES THAT ENHANCE RECALL & LUCIDITY DURING DREAMING

Appn. Filed: 06/27/2003

Serial Number: Patent Agent:

10/604,138 Mark D. Lenhart, # 53203

Applicant:

Stephen LaBerge

Examiner/GAU: MCMILLIAN, KARA RENITA / 1617 Doc #:

ML100

## RESPONSE TO AN ELECTION OF SPECIES RESTRICTION REQUIREMENT

MAIL STOP: AMENDMENT **Commissioner of Patents** P.O. Box 1450 Alexandria, VA 22313-1450

## Sir/Ma'am:

This is a response to the Official Action mailed January 28, 2009. The time for responding Applicant requests a 1 month extension of time under 37 C.F.R. § expires on February 28, 2009. 1.136(a) extending the time for response from February 28th, 2009, to Saturday March 28th, 2009, pursuant to 37 C.F.R. § 1.7. The commissioner is hereby authorized to charge the fee of \$65.00 as set forth in 37 C.F.R. § 1.17(a)(1) for a small entity for this extension. A check is enclosed.

In the last Office Action, Examiner requests two species elections, stating that: Claims 1-10 are generic to the following disclosed patentably distinct species:

- (1) Species of a class of substances that intensify REM sleep (Applicant must choose one disclosed species such as an acetylcholine esterase inhibitor or a cholinergic agonist or a muscarinic receptor agonist, etc);
- (2) Applicant must further elect a single species of a drug from the elected class of drugs that intensify REM sleep (for example, if Applicant chooses the acetylcholine inhibitor as the class of drugs that intensify REM sleep, applicant must further specific acetylcholine esterase inhibitor such as one from those listed in claim 2).

04/02/2009 NNGUYEN1 00000003 10604138

65.00 OP 01 FC:2251

With regards to the first species election requirement, Applicant hereby elects, without

transverse, the Acetylcholine esterase inhibitor species. However, Applicant does wish to state

that the present Patent Application is aimed at the broad class of Acetylcholine neurotransmitter

modulators (line 002 of the specifications), and their ability to influence Lucid Dreaming. Due to

the extremely arcane and sparse nature of dream lucidity prior art, Applicant believes that the few

cited species of Acetylcholine modulators would not create an undue search burden.

With regards of the second species election requirement, by way of this amendment Applicants

elects, with traverse, the Huperzine A species of Acetylcholine modulators. The non-elected species

have been withdrawn without prejudice.

Applicant respectfully wishes to state that Donepizil, Rivastigmin, Galantamine, Tacrine, and

Huperzine are well known Acetylcholine Esterase inhibitors to a person of ordinary skill in the art, and

most all of these compounds share a common empirical formula (CxHyNzOn), as well as an NH2 amine

functional group. Therefore, it is Applicant's suggestion that at least insofar as Donepizil, Rivastigmin,

Galantamine, Tacrine, and Huperzine sub-species of Acetycholine Esterase inhibitors are concerned, a

search of these compound classes would not be burdensome on the Examiner. Accordingly, Applicant

believes that an election of a single species of compound is not required here, and that the examination of

the elected Group I may take place without this requested election. Thus, Applicant respectfully requests

that the Examiners election of species request for the single compound be reconsidered and withdrawn.

Applicant believes that all requirements of patentability are fully met by the pending claims.

The Examiner is invited to contact Applicant's Agent, Mark Lenhart, at 650-450-4430 should

there be any questions about this Response.

Sincerely,

Applicant,

Stephen LaBerge,

c/o

Mark D. Lenhart, Patent Agent

650-450-4430 (phone) / 860-831-9882 (fax) / patents@lenharts.com

2055 Berkeley Way, Berkeley, CA 94704